Business Description
Prestige BioPharma Ltd
ISIN : KR8702070002
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.87 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -27.53 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.13 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year FCF Growth Rate | -42.3 | |||||
3-Year Book Growth Rate | 32.4 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 90.45 | |||||
9-Day RSI | 85.88 | |||||
14-Day RSI | 80.79 | |||||
6-1 Month Momentum % | -17.15 | |||||
12-1 Month Momentum % | -23.18 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.86 | |||||
Quick Ratio | 1.8 | |||||
Cash Ratio | 1.78 | |||||
Days Sales Outstanding | 105.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.1 | |||||
Shareholder Yield % | -7.94 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -376.27 | |||||
Net Margin % | -3918.32 | |||||
FCF Margin % | -10853.95 | |||||
ROE % | -7.29 | |||||
ROA % | -4.42 | |||||
ROIC % | -0.57 | |||||
ROC (Joel Greenblatt) % | -1.02 | |||||
ROCE % | -0.53 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 679.97 | |||||
PB Ratio | 1.28 | |||||
Price-to-Tangible-Book | 1.92 | |||||
EV-to-EBIT | -133.66 | |||||
EV-to-EBITDA | -133.66 | |||||
EV-to-Revenue | 517.85 | |||||
EV-to-FCF | -4.4 | |||||
Earnings Yield (Greenblatt) % | -0.75 | |||||
FCF Yield % | -15.13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Prestige BioPharma Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 825.321 | ||
EPS (TTM) (â‚©) | -233.8 | ||
Beta | 1.3 | ||
Volatility % | 36.73 | ||
14-Day RSI | 80.79 | ||
14-Day ATR (â‚©) | 300.747076 | ||
20-Day SMA (â‚©) | 8294.5 | ||
12-1 Month Momentum % | -23.18 | ||
52-Week Range (â‚©) | 7610 - 14920 | ||
Shares Outstanding (Mil) | 60.1 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Prestige BioPharma Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Prestige BioPharma Ltd Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Prestige BioPharma Ltd Frequently Asked Questions
What is Prestige BioPharma Ltd(XKRX:950210)'s stock price today?
When is next earnings date of Prestige BioPharma Ltd(XKRX:950210)?
Does Prestige BioPharma Ltd(XKRX:950210) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |